The need to consider the wider agenda in systematic reviews and meta-analyses

BMJ (Online)

Volumn 341, Issue 7776, 2010, Pages 762-765

  Ioannidis, John ^a   Karassa, Fotini ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; BEVACIZUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; ONERCEPT; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANKYLOSING SPONDYLITIS; AUTOIMMUNE DISEASE; CLINICAL RESEARCH; COST EFFECTIVENESS ANALYSIS; CROHN DISEASE; DRUG INDICATION; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; META ANALYSIS; PRIORITY JOURNAL; PROGRAM DEVELOPMENT; PSORIASIS; PSORIATIC ARTHRITIS; PUBLICATION; REVIEW; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW; ULCERATIVE COLITIS;

EID: 77957841914     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.c4875     Document Type: Review

References (25)

1. Dwan K, Altman DG, Arnaiz JA, Bloom J, Chan AW, Cronin E, et al. Systematic review of the empirical evidence of study publication bias and outcome reporting bias. PLoS One 2008;3:e3081.
2. Ioannidis JP. Why most published research findings are false. PLoS Med 2005;2:e124.
3. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 2008;358:252-60.
4. Bassler D, Briel M, Montori VM, Lane M, Glasziou P, Zhou Q, et al. STOPIT-2 Study Group. Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. JAMA 2010;303:1180-7.
5. Hughes MD, Pocock SJ. Stopping rules and estimation problems in clinical trials. Stat Med 1988;7:1231-1242.
6. Ioannidis JP. Why most discovered true associations are inflated. Epidemiology 2008;19:640-648.
7. Ioannidis JP. Effect of the statistical significance of results on the time to completion and publication of randomized efficacy trials. JAMA 1998;279:281-286.
8. Sfikakis PP. The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions. Curr Dir Autoimmun 2010;11:180-210.
9. Barra L, Pope JE, Payne M. Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire. J Rheumatol 2009;36:1421-8.
10. Abbott. 2009 Annual Report. http://www.abbott.com/annual-reports/2009/ downloads/Editorial-section-only.pdf (accessed 6 May, 2010)
11. Genentech Inc., K-10 form. http://www.sec.gov/Archives/edgar/data/318771/ 000031877109000003/form10-k-2008.htm (accessed 31 March 2010)
12. Huedo-Medina TB, Sánchez-Meca J, Marín-Martínez F, Botella J. Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol Methods 2006;11:193-206.
13. Tappenden P, Jones R, Paisley S, Carroll C. The cost-effectiveness of bevacizumab in the first-line treatment of metastatic colorectal cancer in England and Wales. Eur J Cancer 2007;43:2487-94.
14. Ranpura V, Pulipati B, Chu D, Zhu X, Wu S. Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis. Am J Hypertens 2010; 25 Feb. [Epub ahead of print]
15. Ranpura V, Hapani S, Chuang J, Wu S. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: A meta-analysis of randomized controlled trials. Acta Oncol 2010; 16 Feb. [Epub ahead of print]
16. Hapani S, Chu D, Wu S. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol 2009;10:559-68.
17. Ioannidis JP, Patsopoulos NA, Rothstein HR. Reasons or excuses for avoiding meta-analysis in forest plots. BMJ 2008;336:1413-5.
18. Rennie D. Trial registration: a great idea switches from ignored to irresistible. JAMA 2004;292:1359-62.
19. Laine C, Horton R, DeAngelis CD, Drazen JM, Frizelle FA, Godlee F, et al. Clinical trial registration: looking back and moving ahead. Lancet 2007;369:1909-11.
20. Ioannidis JP. Effectiveness of antidepressants: an evidence myth constructed from a thousand randomized trials? Philos Ethics Humanit Med 2008; 27 May:3:14.
21. Sutton AJ, Cooper NJ, Jones DR. Evidence synthesis as the key to more coherent and efficient research. BMC Med Res Methodol 2009;9:29.
22. Salanti G, Kavvoura FK, Ioannidis JP. Exploring the geometry of treatment networks. Ann Intern Med 2008;148:544-53.
23. Ioannidis JP. Integration of evidence from multiple meta-analyses: a primer on umbrella reviews, treatment networks and multiple treatments meta-analyses. CMAJ 2009;181:488-93.
24. Dias S, Welton NJ, Caldwell DM, Ades AE. Checking consistency in mixed treatment comparison meta-analysis. Stat Med 2010;29:932-44.
25. Lathyris DN, Patsopoulos NA, Salanti G, Ioannidis JP. Industry sponsorship and selection of comparators in randomized clinical trials. Eur J Clin Invest 2010;40:172-82.